Details of Disease

General Information of Disease (ID: DISS0RQZ)

• Disease Name: Postmenopausal osteoporosis
• Synonyms: bone mineral density quantitative trait locus; osteoporosis, postmenopausal
• Disease Class: FB83: Low bone mass disorder
• Definition: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
• Disease Hierarchy:
  DISF2JE0: Osteoporosis
  DISS0RQZ: Postmenopausal osteoporosis
• ICD Code:
  ICD-11: ICD-11: FB83.11
  ICD-10: ICD-10: M81.0
  ICD-9: ICD-9: 733
  Expand ICD-11: 'FB83.11
  Expand ICD-10: 'M81.0
  Expand ICD-9: 733
• Disease Identifiers:
  MONDO ID: MONDO_0008159
  MESH ID: D015663
  UMLS CUI: C0029458
  MedGen ID: 10498
  SNOMED CT ID: 102447009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abaloparatide	DMOERGM	Approved	Recombinant protein	[1]
Calcitonin Human	DM0N9WA	Approved	NA	[2]
Denosumab	DMNI0KO	Approved	Antibody	[3]
Romosozumab	DMFJZN0	Approved	Antibody	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CAT	TTPS279	Limited	Biomarker	[6]
COL1A2	TTUABC1	Limited	Genetic Variation	[7]
PTH	TT6F7GZ	Limited	Biomarker	[8]
ADRB1	TTR6W5O	Strong	Biomarker	[9]
ARHGEF3	TT1R5DZ	Strong	Biomarker	[10]
CLCF1	TTI6V13	Strong	Biomarker	[11]
FNDC1	TTQJCV8	Strong	Altered Expression	[12]
GJA4	TTQO1VY	Strong	Biomarker	[13]
GPR87	TTO897C	Strong	Biomarker	[9]
LGMN	TTPTWV5	Strong	Altered Expression	[14]
MTNR1B	TT32JK8	Strong	Biomarker	[15]
PTGER4	TT79WV3	Strong	Therapeutic	[16]
PTH1R	TTFPD47	Strong	Biomarker	[17]
PTK2B	TTTEFBV	Strong	Biomarker	[18]
REL	TT1ZCTH	Strong	Biomarker	[19]
SOST	TTYRO4F	Strong	Biomarker	[20]
TMPRSS6	TTL9KE7	Strong	Biomarker	[15]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[21]
TNFRSF11B	TT2CJ75	Strong	Altered Expression	[22]
VDR	TTK59TV	Strong	Genetic Variation	[23]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACP5	DESITDW	Strong	Biomarker	[24]

This Disease Is Related to 26 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
COL1A1	OTI31178	Limited	Altered Expression	[25]
RPS5	OTPSWQRS	Limited	Biomarker	[26]
SQOR	OTTLD0KB	Limited	Biomarker	[27]
ADGRF5	OTWU7AOO	Strong	Biomarker	[9]
C4orf3	OT6TFN1O	Strong	Genetic Variation	[28]
CACNG1	OT6OCR3H	Strong	Biomarker	[29]
COL9A1	OTWBR27Y	Strong	Genetic Variation	[30]
CPQ	OTTNZNLD	Strong	Biomarker	[11]
DHTKD1	OTDQLSNT	Strong	Biomarker	[9]
EGR3	OTGPJIRA	Strong	Genetic Variation	[31]
GNAI2	OTTLGRGH	Strong	Biomarker	[32]
IBSP	OT29944Y	Strong	Genetic Variation	[33]
IL18BP	OTW0LRYZ	Strong	Biomarker	[34]
IL36A	OTHBEL5H	Strong	Genetic Variation	[35]
ITLN1	OT7ZLJVV	Strong	Genetic Variation	[36]
LGALS8	OT71LJ8T	Strong	Biomarker	[37]
MAP9	OTZD5099	Strong	Biomarker	[38]
NEO1	OTGJ1997	Strong	Biomarker	[9]
NRIP1	OTIZOJQV	Strong	Biomarker	[39]
PPWD1	OTA7CG42	Strong	Biomarker	[40]
PTHLH	OTI1JF13	Strong	Biomarker	[41]
PTRH1	OTOAOS93	Strong	Biomarker	[42]
RBBP4	OTG3BT3M	Strong	Biomarker	[9]
RDX	OTNSYUN6	Strong	Biomarker	[43]
SLIT3	OTU8MKEU	Strong	Biomarker	[44]
TRIM63	OTUSWA74	Strong	Biomarker	[29]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6886).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013 May;121(5):959-68.
• [6] Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Arch Med Res. 2007 Feb;38(2):196-205.
• [7] Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta.Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5423-7. doi: 10.1073/pnas.88.12.5423.
• [8] Effects of sequential treatment with intermittent parathyroid hormone and zoledronic acid on particle-induced implant loosening: Evidence from a rat model.J Orthop Res. 2019 Jul;37(7):1489-1497. doi: 10.1002/jor.24217. Epub 2019 Apr 17.
• [9] Identification of gene biomarkers in patients with postmenopausal osteoporosis.Mol Med Rep. 2019 Feb;19(2):1065-1073. doi: 10.3892/mmr.2018.9752. Epub 2018 Dec 12.
• [10] Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis.Am J Hum Genet. 2008 Jun;82(6):1262-9. doi: 10.1016/j.ajhg.2008.04.016. Epub 2008 May 22.
• [11] Liuwei Dihuang Pill () Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression.Chin J Integr Med. 2018 Jun;24(6):415-422. doi: 10.1007/s11655-016-2744-2. Epub 2016 Dec 27.
• [12] Rutin suppresses FNDC1 expression in bone marrow mesenchymal stem cells to inhibit postmenopausal osteoporosis.Am J Transl Res. 2019 Oct 15;11(10):6680-6690. eCollection 2019.
• [13] Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men.Int J Mol Med. 2007 May;19(5):791-801.
• [14] Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis.Stem Cell Reports. 2017 Feb 14;8(2):373-386. doi: 10.1016/j.stemcr.2017.01.003. Epub 2017 Feb 2.
• [15] Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway.J Pineal Res. 2017 Sep;63(2):e12423. doi: 10.1111/jpi.12423. Epub 2017 Jun 20.
• [16] Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4580-5. doi: 10.1073/pnas.062053399. Epub 2002 Mar 26.
• [17] Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.Osteoporos Int. 2018 Mar;29(3):685-697. doi: 10.1007/s00198-017-4323-6. Epub 2017 Dec 19.
• [18] Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10619-24. doi: 10.1073/pnas.0701421104. Epub 2007 May 30.
• [19] Identification of crucial genes related to postmenopausal osteoporosis using gene expression profiling.Aging Clin Exp Res. 2016 Dec;28(6):1067-1074. doi: 10.1007/s40520-015-0509-y. Epub 2015 Dec 16.
• [20] Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!.Nephrol Dial Transplant. 2019 Mar 1;34(3):408-414. doi: 10.1093/ndt/gfy129.
• [21] l-tetrahydropalmatine suppresses osteoclastogenesis in vivo and in vitro via blocking RANK-TRAF6 interactions and inhibiting NF-B and MAPK pathways.J Cell Mol Med. 2020 Jan;24(1):785-798. doi: 10.1111/jcmm.14790. Epub 2019 Nov 14.
• [22] Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway.Int J Biol Macromol. 2019 May 15;129:579-587. doi: 10.1016/j.ijbiomac.2019.02.022. Epub 2019 Feb 5.
• [23] Associations between VDR Gene Polymorphisms and Osteoporosis Risk and Bone Mineral Density in Postmenopausal Women: A systematic review and Meta-Analysis.Sci Rep. 2018 Jan 17;8(1):981. doi: 10.1038/s41598-017-18670-7.
• [24] Evidence-based assessment of antiosteoporotic activity of petroleum-ether extract of Cissus quadrangularis Linn. on ovariectomy-induced osteoporosis.Ups J Med Sci. 2009;114(3):140-8. doi: 10.1080/03009730902891784.
• [25] MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells.J Cell Biochem. 2020 Feb;121(2):1216-1226. doi: 10.1002/jcb.29355. Epub 2019 Sep 3.
• [26] A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5.Front Pharmacol. 2018 Jan 30;9:22. doi: 10.3389/fphar.2018.00022. eCollection 2018.
• [27] Genetic susceptibility of postmenopausal osteoporosis on sulfide quinone reductase-like gene.Osteoporos Int. 2018 Sep;29(9):2041-2047. doi: 10.1007/s00198-018-4575-9. Epub 2018 May 31.
• [28] Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.Medicine (Baltimore). 2018 Aug;97(31):e11694. doi: 10.1097/MD.0000000000011694.
• [29] In silico analysis of the molecular mechanism of postmenopausal osteoporosis.Mol Med Rep. 2015 Nov;12(5):6584-90. doi: 10.3892/mmr.2015.4283. Epub 2015 Sep 2.
• [30] Relationship of COL9A1 and SOX9 Genes with Genetic Susceptibility of Postmenopausal Osteoporosis.Calcif Tissue Int. 2020 Mar;106(3):248-255. doi: 10.1007/s00223-019-00629-7. Epub 2019 Nov 15.
• [31] ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.Endocr Pract. 2017 Jun;23(6):657-661. doi: 10.4158/EP161394.OR. Epub 2017 Feb 22.
• [32] Bioinformatics analysis of gene expression profiles in B cells of postmenopausal osteoporosis patients.Taiwan J Obstet Gynecol. 2017 Apr;56(2):165-170. doi: 10.1016/j.tjog.2016.04.038.
• [33] Endochondral ossification pathway genes and postmenopausal osteoporosis: Association and specific allele related serum bone sialoprotein levels in Han Chinese.Sci Rep. 2015 Nov 16;5:16783. doi: 10.1038/srep16783.
• [34] IL-18BP is decreased in osteoporotic women: Prevents Inflammasome mediated IL-18 activation and reduces Th17 differentiation.Sci Rep. 2016 Sep 21;6:33680. doi: 10.1038/srep33680.
• [35] Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study.Bone. 2002 Jul;31(1):43-50. doi: 10.1016/s8756-3282(02)00810-4.
• [36] Omentin Polymorphism and its Relations to Bone Mineral Density in Women.Arch Med Res. 2015 Apr;46(3):173-80. doi: 10.1016/j.arcmed.2015.03.012. Epub 2015 May 14.
• [37] Ablation of the mammalian lectin galectin-8 induces bone defects in mice.FASEB J. 2018 May;32(5):2366-2380. doi: 10.1096/fj.201700716R. Epub 2017 Dec 19.
• [38] MiR-320a was highly expressed in postmenopausal osteoporosis and acts as a negative regulator in MC3T3E1 cells by reducing MAP9 and inhibiting PI3K/AKT signaling pathway.Exp Mol Pathol. 2019 Oct;110:104282. doi: 10.1016/j.yexmp.2019.104282. Epub 2019 Jul 10.
• [39] Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis.Bone. 2006 Jul;39(1):213-21. doi: 10.1016/j.bone.2005.12.079. Epub 2006 Mar 10.
• [40] PPWD1 is associated with the occurrence of postmenopausal osteoporosis as determined by weighted gene coexpression network analysis.Mol Med Rep. 2019 Oct;20(4):3202-3214. doi: 10.3892/mmr.2019.10570. Epub 2019 Aug 7.
• [41] Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.Osteoporos Int. 2019 Aug;30(8):1607-1616. doi: 10.1007/s00198-019-04999-4. Epub 2019 May 3.
• [42] In vivo and in vitro effects of PTH1-34 on osteogenic and adipogenic differentiation of human bone marrow-derived mesenchymal stem cells through regulating microRNA-155.J Cell Biochem. 2018 Apr;119(4):3220-3235. doi: 10.1002/jcb.26478. Epub 2018 Jan 2.
• [43] Bioinformatics Analysis Reveals the Altered Gene Expression of Patients with Postmenopausal Osteoporosis Using Liuweidihuang Pills Treatment.Biomed Res Int. 2019 Jan 27;2019:1907906. doi: 10.1155/2019/1907906. eCollection 2019.
• [44] Targeting skeletal endothelium to ameliorate bone loss.Nat Med. 2018 Jun;24(6):823-833. doi: 10.1038/s41591-018-0020-z. Epub 2018 May 21.